• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Tilray Is Now a Top-Tier Cannabis Play

I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.
By TIMOTHY COLLINS
Dec 20, 2018 | 02:22 PM EST
Stocks quotes in this article: TLRY, BUD, STZ, CGC, TAP, HYYDF, MO, CRON, NVS

Tilray (TLRY) is a ray of sunshine on an otherwise cloudy week in the market. A green ray of sunshine.

The stock is benefiting from three announcements this month, two of which are major and came this week.

The biggest boost to the stock has come from the announced partnership with Anheuser-Busch InBev (BUD) . Both BUD and TLRY will contribute $50 million to research non-alcoholic beverages containing cannabis extracts. These could be drinks with cannabidiol (CBD) and/or Tetrahydrocannabinol (THC). (The latter of those two is what gives people a high.)

Current expectations are Canada will approve CBD beverages in October 2019 along with edibles. By teaming up with Labatt's Brewing, a subsidiary of BUD, the duo could be poised to jump into what is seen as a potentially huge market immediately after legalization.

Tilray isn't the first cannabis company to team up with an alcoholic beverage brewer. Constellation Brands in (STZ) has poured $4 billion into Canopy Growth (CGC) while Molson (TAP) has a joint venture in place with Hexo (HYYDF) for CBD/THC beverages. While not in the same category of beverages, we shouldn't neglect Altria's (MO) $1.8 billion stake in Cronos (CRON) as well. The Tilray-BUD joint venture is another reminder how 11-figure and 12-figure sized companies are aggressively entering the cannabis space.

Unlike Cronos and Canopy, Tilray is putting money into this venture rather than receiving an investment. While that is probably better for the bottom line in the long run, Tilray doesn't possess the same war chest as Canopy and Cronos. This leads me to believe we'll see a cap raise very soon. The BUD joint venture will eat up about half of Tilray's cash.

In a smaller move, the company invested $7.5 million into ROSE LifeSciences to expand much needed supply. Again, another outflow of cash. Good for the long-term vision, but pushing the need for additional capital.

Last on the list of recent moves is the partnership with Novartis (NVS) branch Sandoz to develop and distribute medical marijuana worldwide. Novartis is going to bring a huge worldwide marketing staff, or feet on the ground as some might call it. This is similar to the BUD deal. BUD offers marketing and distribution worldwide. These combinations will save significant future dollars that would be needed for staffing, training, and execution. I basically see these joint ventures as front-end expenditures for marketing and distribution that would cost more to build than buy.

Overall, the moves cement Tilray as a top-tier cannabis play. I do believe the company should and will raise capital with a valuation hovering around $6.5 billion. Given sale for next year will likely be somewhere around $65-75 million with the company posting a loss; much of the coming hyper growth in the cannabis sector is priced into the stock. While the recent developments are bullish for the long-term, I suspect the short-term squeeze and momentum will fade soon. I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019. Until then, I still favor Canopy Growth and Cronos although I do believe selling far out-of-the-money puts on Tilray for January or February expiration is a viable strategy. That's the only one I would pursue currently on this name.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Timothy Collins had no position in the securities mentioned.

TAGS: Investing | Markets | Options | Stocks | Trading | Cannabis | Stock of the Day

More from Investing

Market Looks Good from Above, Poor From Below

James "Rev Shark" DePorre
Jun 29, 2022 4:21 PM EDT

The major indexes held up well, but underneath, it wasn't pretty.

This FAANG Stock's Technicals Are at a Summer Crossroads

Bob Lang
Jun 29, 2022 3:30 PM EDT

Summer is a time when this name usually gains momentum. Will it this time?

Kass: Untapped Homeowners Equity and Imbedded Gains Will Be a Ballast to Growth

Doug Kass
Jun 29, 2022 3:00 PM EDT

Homeowners equity has more than tripled in the last decade.

Can Pinterest Poke Through the Charts and Rally?

Bruce Kamich
Jun 29, 2022 2:48 PM EDT

With a CEO change in the mix, shares hit, and a social media under watch, let's see whether PINS could move the needle.

Let's Process Nvidia's New Low

Bruce Kamich
Jun 29, 2022 1:47 PM EDT

NVDA moves down, so let's check the charts -- and see why we should take too much bearishness with a grain of salt.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:51 PM EDT PAUL PRICE

    We should be in for better starting soon.

    Window dressing tomorrow, the last day of ...
  • 11:56 AM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    Check out what's going on in the Stocks Under $10 ...
  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login